ANN ARBOR, MI--(Marketwire - March 31, 2010) - Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company developing new medicines for serious central nervous system diseases announced today that it will hold an investor conference call on Thursday, April 1, 2010 at 9:00 a.m. EDT. James S. Kuo, Chairman and Chief Executive Officer of Adeona, will host the call.
In order to participate in the conference call, please call toll free: 888-211-4542 (US); international dial-in: 913-312-0684, conference ID. 7646444. The audio recording will be available for replay at http://www.adeonapharma.com for a period of at least 15 days after the call.
About Adeona Pharmaceuticals, Inc.
Adeona Pharmaceuticals, Inc., a Nevada corporation, ("Adeona" or the "Company") is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them further to either commercialization or a development collaboration. Trimesta (estriol) is an investigational oral drug for the treatment of relapsing remitting multiple sclerosis. A 150-patient, 16-center, randomized, double-blind, placebo-controlled clinical trial is currently underway. Zinthionein™ ZC (zinc cysteine) is an oral, gastro-retentive, sustained-release medical food candidate being developed for the dietary management of Alzheimer's disease and mild cognitive impairment. In December of 2009, Adeona initiated a 60-patient clinical study. Effirma (flupirtine) is a novel centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. It is ready for a 90-patient proof-of-concept clinical trial. dnaJP1 (hsp peptide) is an investigational oral drug for the treatment of rheumatoid arthritis. It has completed a 160-patient, multi-center, randomized, double-blind, placebo-controlled clinical trial. CD4 Inhibitor 802-2 (cyclic heptapeptide) is an investigational drug for the prevention of severe graft-versus-host disease. A 23-patient clinical trial has been completed.
For Further Information Contact:
James S. Kuo
Chairman and Chief Executive Officer
(734) 332-7800
